Predictive and Prognostic Value of Sphingosine Kinase 1 Expression in Patients with Invasive Ductal Carcinoma of the Breast

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2018 Jan 10

PMID 29312521

Citations 7

Authors

Sung-Im DO

Hyun-Soo Kim

Kyungeun Kim

Hyunjoo Lee

In-Gu Do

Dong-Hoon Kim

Seoung Wan Chae

Jin Hee Sohn

Affiliations

Soon will be listed here.

Abstract

Sphingosine kinase 1 (SPHK1) has been found to be upregulated in many different types of human malignancy and plays a crucial role in cancer development and progression. However, the potential of SPHK1 to act as a predictive and prognostic biomarker in breast cancer remains to be clarified. In the present study, SPHK1 expression was evaluated in breast cancer cell lines and 224 breast cancer tissue samples using immunohistochemical staining. Compared to the normal mammary epithelial cell line MCF-10A, SPHK1 mRNA and protein expression levels increased in the breast cancer cell lines SK-BR-3, MDA-MB-231, MDA-MB-436, and MCF-7. Immunohistochemical staining revealed SPHK1 expression to be significantly increased in breast cancer tissue compared to normal breast tissue, with 85 (37.9%) of the 224 invasive ductal carcinomas (IDC) exhibiting high SPHK1 expression. High SPHK1 expression in IDC showed a significant association with higher histological grade, distant metastasis, and triple negativity, and was shown to be an independent predictor for distant metastasis development. In addition, patients with high SPHK1 expression had significantly lower progression-free survival and overall survival rates compared to those with low SPHK1 expression. Our data suggest that SPHK1 is involved in the development and progression of breast cancer and can serve as a potential predictive biomarker of distant metastasis and patient outcome.

Citing Articles

Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells.

Hii L, Chung F, Mai C, Ng P, Leong C Front Mol Biosci. 2021; 8:748470.

PMID: 34820423 PMC: 8606534. DOI: 10.3389/fmolb.2021.748470.

Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer.

Velazquez F, Zhang L, Viscardi V, Trocchia C, Hannun Y, Obeid L PLoS One. 2021; 16(5):e0252311.

PMID: 34043703 PMC: 8158862. DOI: 10.1371/journal.pone.0252311.

The Importance of Sphingosine Kinase in Breast Cancer: A Potential for Breast Cancer Management.

Patel D, Ahmad F, Abu Sneineh M, Patel R, Rohit Reddy S, Llukmani A Cureus. 2021; 13(2):e13413.

PMID: 33758708 PMC: 7978154. DOI: 10.7759/cureus.13413.

Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.

Alshaker H, Thrower H, Pchejetski D Front Oncol. 2020; 10:289.

PMID: 32266132 PMC: 7098968. DOI: 10.3389/fonc.2020.00289.

Silencing of the long non-coding RNA RHPN1-AS1 suppresses the epithelial-to-mesenchymal transition and inhibits breast cancer progression.

Zheng S, Lv P, Su J, Miao K, Xu H, Li M Am J Transl Res. 2019; 11(6):3505-3517.

PMID: 31312362 PMC: 6614656.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J . Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 2008; 23(2):405-14. PMC: 2630788. DOI: 10.1096/fj.08-117572. View

Malavaud B, Pchejetski D, Mazerolles C, de Paiva G, Calvet C, Doumerc N . Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 2010; 46(18):3417-24. DOI: 10.1016/j.ejca.2010.07.053. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013; 138(2):241-56. PMC: 4086638. DOI: 10.5858/arpa.2013-0953-SA. View

Yoon N, Kim J, Kim H . Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: a need for reappraisal. Oncotarget. 2016; 7(48):78448-78454. PMC: 5346652. DOI: 10.18632/oncotarget.12905. View

Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim T, Murate T . High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun. 2006; 342(4):1284-90. DOI: 10.1016/j.bbrc.2006.02.070. View

Van Brocklyn J, Jackson C, Pearl D, Kotur M, Snyder P, Prior T . Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005; 64(8):695-705. DOI: 10.1097/01.jnen.0000175329.59092.2c. View

Bayerl M, Bruggeman R, Conroy E, Hengst J, King T, Jimenez M . Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma. 2008; 49(5):948-54. DOI: 10.1080/10428190801911654. View

10.

Tamashiro P, Furuya H, Shimizu Y, Iino K, Kawamori T . The impact of sphingosine kinase-1 in head and neck cancer. Biomolecules. 2014; 3(3):481-513. PMC: 4030949. DOI: 10.3390/biom3030481. View

11.

Gault C, Obeid L . Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy. Crit Rev Biochem Mol Biol. 2011; 46(4):342-51. PMC: 3144498. DOI: 10.3109/10409238.2011.597737. View

12.

Kim E, Yoon G, Kim H . Chemotherapy-induced endometrial pathology: mimicry of malignancy and viral endometritis. Am J Transl Res. 2016; 8(5):2459-67. PMC: 4891460. View

13.

Pyne N, Pyne S . Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10(7):489-503. DOI: 10.1038/nrc2875. View

14.

DO S, Yoon G, Kim H, Kim K, Lee H, Do I . Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast. Anticancer Res. 2016; 36(9):4873-82. DOI: 10.21873/anticanres.11051. View

15.

Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J . Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer. 2010; 10:495. PMC: 2949806. DOI: 10.1186/1471-2407-10-495. View

16.

Kohno M, Momoi M, Oo M, Paik J, Lee Y, Venkataraman K . Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol. 2006; 26(19):7211-23. PMC: 1592880. DOI: 10.1128/MCB.02341-05. View

17.

Li W, Yu C, Xia J, Zhang L, Weng G, Zheng H . Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009; 15(4):1393-9. DOI: 10.1158/1078-0432.CCR-08-1158. View

18.

Kim H, Yoon G, Ryu J, Cho Y, Choi J, Lee Y . Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget. 2015; 6(29):26746-56. PMC: 4694949. DOI: 10.18632/oncotarget.4818. View

19.

Pyne N, Tonelli F, Lim K, Long J, Edwards J, Pyne S . Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans. 2012; 40(1):94-100. DOI: 10.1042/BST20110602. View

20.

Li J, Guan H, Gong L, Song L, Zhang N, Wu J . Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008; 14(21):6996-7003. DOI: 10.1158/1078-0432.CCR-08-0754. View